Introduction
============

Retinoblastoma (RB) is a malignant tumor of the retina and generally affects children under the age of 6 years, worldwide, with an incidence of 1:16,000-1:18,000 and 7,000-8,000 new cases every year ([@b1-etm-0-0-8992]). RB is a threat to both the eyesight and life of children ([@b2-etm-0-0-8992]). Clinical treatments for RB include chemotherapy, radiotherapy, surgery, laser treatment and freezing ([@b3-etm-0-0-8992]). Among them, chemotherapy serves an important role in the management of RB, and vincristine (VCR) is one the most commonly used chemotherapy drugs ([@b7-etm-0-0-8992],[@b8-etm-0-0-8992]). However, the inherent or acquired resistance of tumor cells to chemotherapeutic agents can lead to treatment failure ([@b9-etm-0-0-8992]).

The SO-Rb50 cell line is a human RB cell line. SO-Rb50 cells that are resistant to vincristine (SO-Rb50/VCR) can be established by maintaining the cells in increasing concentrations of vincristine over a period of nine months ([@b12-etm-0-0-8992]). P-glycoprotein (P-gp) is an important protein that indicates multidrug resistance ([@b13-etm-0-0-8992]). It is of particular relevance to the treatment of RB to identify a compound that can effectively target SO-Rb50/VCR cells.

Matrine is a type of alkaloid found in *Leguminosae* plants, including *Sophora flavescens Ait* ([@b14-etm-0-0-8992],[@b15-etm-0-0-8992]). A number of studies have reported the beneficial effects of matrine on the quality of life and immune functions of patients with cancer ([@b16-etm-0-0-8992],[@b17-etm-0-0-8992]). Additionally, matrine has been reported to inhibit tumor cell proliferation through a variety of mechanisms, including inducing cancer cell differentiation and apoptosis, altering tumor cell cycle and inhibiting telomerase activity ([@b18-etm-0-0-8992]). Therefore, matrine may be a suitable compound for use in the treatment of a number of cancer types or cancer-related conditions. The present study demonstrated that matrine inhibited the proliferation of immortalized RB cells, decreased the rate of mitosis and increased apoptosis, which was also paralleled by corresponding changes in levels of the proteins regulating the cell cycle and apoptosis in the immortalized RB cells ([@b22-etm-0-0-8992]). However, to the best of our knowledge, the effects of matrine on VCR-resistant RB cells have not previously been reported. Therefore, the present study aimed to identify the various effects of matrine on SO-Rb50/VCR cells.

Materials and methods
=====================

### Establishment of drug-resistant cell lines

SO-RB50 cells were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences and cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Hyclone; GE Healthcare Life Sciences) and 100 U/ml penicillin-streptomycin (Sigma-Aldrich; Merck KGaA) in 5% CO~2~ at 37˚C. Drug-resistance in SO-Rb50 cells was induced by stimulation with increasing concentrations of VCR (National Institutes for Food and Drug Control) at 37˚C, ranging from 75 µg/l to 600 µg/l, over \~9 months, as previously described ([@b23-etm-0-0-8992],[@b12-etm-0-0-8992]). Cells receiving normal culture medium without any treatment were utilized as controls. The wells without cells and culture medium were used as blank controls.

### Cell growth and proliferation

SO-Rb50/VCR cells were cultured *in vitro* as aforementioned, and the cell growth curve was measured after treatment with matrine at different concentrations. SO-Rb50/VCR cells (3x10^3^/ml) in the logarithmic growth phase were inoculated onto 96-well plates (50 µl /well). The cells were incubated with matrine at different concentrations at 37˚C (50 µl, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1 and 1.3 mg/ml). CCK-8 assay (Dojindo Molecular Technologies, Inc.) was used to analyze the cytotoxicity of matrine in accordance with the manufacturers protocol, and half-maximal inhibitory concentration (IC~50~) was calculated. The optimal drug concentration (determined based on the IC~50~; 0.97 mg/ml) was identified and selected for subsequent experiments.

Cell viability was calculated according to the following formula. Cell viability (%)=\[(As-Ab)/(Ac-Ab)\] x 100%, in which 'As' is the absorbance of the experimental group, Ac is the absorbance of the control group (containing cell culture medium, CCK-8), Ab is the blank group (without cell and matrine solution culture medium, CCK-8). Inhibitory rate of cell proliferation =100-cell viability.

### TUNEL assay

The level of cell apoptosis was evaluated before and after administration of matrine (0.97 mg/ml; IC~50~) for 0, 12, 24 and 48 h. The cells were collected, fixed in 4% paraformaldehyde at room temperature for 30 min and stained using TUNEL (37˚C for 5 min)/DAPI (1 mg/ml for 5 min). Subsequently, apoptosis was detected using flow cytometry (BD Biosciences) within 1 h and analyzed using FlowJo v7.6 software (FlowJo LLC).

### Cell cycle analysis

The cultured SO-Rb50/VCR cells were treated with matrine (0.97 mg/ml, IC~50~), and the cell cycle of cells without matrine treatment (control) and after treatment was assessed by flow cytometry (BD Biosciences) after PI (Merck KGaA) staining for 5 min protected from light at room temperature. The data were analyzed using FlowJo v7.6 software (FlowJo LLC).

### Electron microscopic examination

To examine the cells using electron microscopy, the cells treated with matrine or vehicle were centrifuged (1,000 x g at 4˚C for 8 min), fixed with 3% glutaraldehyde at 4˚C for 2 h. For the preparation of ultra-thin sections (1 µm), the cells were washed with phosphate-buffered saline, fixed with 1% osmic acid for 1 h at 4˚C, dehydrated with acetone and embedded in epoxide resin. After staining with uranyl acetate and lead citrate at room temperature for 5 min, the sections were observed in at least least five fields under a transmission electron microscope (model no. EM208s; Koninklijke Philips N.V.). The images were processed using Image J (v150-win-jre6; National Institutes of Health).

### Western blot analysis

Cultured SO-Rb50/VCR cells were treated with matrine (0.97 mg/ml; IC~50~) for 0, 12, 24 and 48 h and protein was extracted from cell lines for western blot analysis using the triplePrep kit (cat. no. 28-9425-44; GE Healthcare Life Sciences). The 0 time point was set as control. Protein concentration was then determined using the bicinchoninic acid method. Protein (25 µg/lane) was subsequently separated via 10% SDS-PAGE and transferred onto nitrocellulose membranes. Thereafter, the membranes were blocked in 5% skimmed milk for 2 h at room temperature. The following antibodies were used for incubation for 24 h at 4˚C: Bcl-2 (1:200; cat. no. ab117115, Abcam), Bax (1:200; cat. no. ab32503; Abcam) and β-actin (1:200; cat. no. ab179467; Abcam). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG H&L (1:100; cat. no. ab205719; Abcam) or HRP-conjugated goat anti-rabbit IgG H&L (1:100; cat. no. ab6721; Abcam) were added and co-incubated for 1-2 h at room temperature. ECL Plus Western Blotting Reagent (cat. no. RPN2133; GE Healthcare Life Sciences) was added to the membrane. The bands were visualized utilizing a gel imaging system (Bio-Rad Laboratories, Inc.). Grey density was analyzed using Quantity One analysis software v1.4.6 (Bio-Rad Laboratories, Inc.).

### Statistical analysis

The data are presented as mean ± S.E.M (n=6 in each group; analyses were performed in triplicate), and were analyzed using SPSS 17.0 (SPSS, Inc.). Significant differences between two groups were calculated by *t*-test. When three or more groups were compared, one-way ANOVA was applied to the data, followed by Tukey\'s post-hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Establishment and detection of drug-resistant cell lines

SO-Rb50 cells grew in suspension with grape-like clusters, displaying large-size and uniform pattern. Following treatment with VCR, mass clusters of SO-Rb50 were disturbed and the cells presented mostly in the form of small clusters or single cells. The cell growth was significantly slower, and the cells became uneven in size following VCR treatment. However, the inhomogeneity of cell size became more obvious and there are more degenerative cells and cell debris after 4 to 6 days. A few cells lost their original shape and vacuolar structures appeared in the cytoplasm and the nuclear structure became unclear. These cells gradually increased with time, but there was no increase in the number of these cells during the following three weeks. After treatment for three weeks, the medium (with VCR) was washed away and replaced with fresh medium for further cell growth. The growth of SO-Rb50 cells was still slow at the beginning, but gradually recovered over time (after \~2-3 weeks). At the same time, the abnormal morphology was gradually decreased or even disappeared; the cells were more uniform in size and the cell mass became larger. The above changes occurred again after increasing the concentration of drugs. SO-Rb50 cells could grow stably in the medium containing 600 g/ml of VCR after an intermittent treatment with different concentrations (data not shown).

The IC~50~ values of VCR on SO-Rb50 and SO-Rb50/VCR cells for 48 h were 122±17.1 µg/ml and 1720±77.4 µg/ml, respectively. The tolerance of SO-Rb50/VCR cells to VCR was \~14.1 times higher than that of SO-Rb50 ([Fig. 1A](#f1-etm-0-0-8992){ref-type="fig"}). P-gp protein expression was relatively low in untreated SO-Rb50 cells, but the level of P-gp protein increased significantly after an increase in VCR concentration ([Fig. 1B](#f1-etm-0-0-8992){ref-type="fig"}).

### Effect of matrine on cell proliferation

As indicated in [Fig. 2A](#f2-etm-0-0-8992){ref-type="fig"}, matrine (0.3-1.3 mg/ml over 24 h) exhibited significantly suppressive effects on cellular growth of SO-Rb50 and SO-Rb50/VCR cells in a dose-dependent manner, and the IC~50~ values of matrine on SO-Rb50 and SO-Rb50/VCR cells for 24 h were 0.96±0.04 mg/ml and 0.97±0.08 mg/ml, respectively ([Fig. 2A](#f2-etm-0-0-8992){ref-type="fig"}). There was no significant difference indicated in the proliferation-inhibition of matrine in SO-Rb50 and SO-Rb50/VCR cells ([Fig. 2A](#f2-etm-0-0-8992){ref-type="fig"}). SO-Rb50/VCR cells grew as suspended aggregates in a uniform pattern with large nuclei. After treatment with matrine (IC~50~) for 24 h, the cell mass was reduced, the cells became uneven in size and cytoplasmic debris and vacuolated cells were observed ([Fig. 2B](#f2-etm-0-0-8992){ref-type="fig"}).

### Effect of matrine on apoptosis and the cell cycle

The ultrastructures of SO-Rb50/VCR cells in the control group and the matrine-treated group was observed using electron microscopy, and the cells exhibited significant degeneration, demonstrating features of apoptosis (chromatin condensation and vacuolar accumulation) after drug treatment compared with control group ([Fig. 3A](#f3-etm-0-0-8992){ref-type="fig"}).

The results of a TUNEL assay indicated that the apoptosis rates of SO-Rb50/VCR cells in the control group and the matrine-treated (at IC~50~ concentration) group at 12, 24 and 48 were 0.13, 3.2, 20.2 and 28.8%, respectively ([Fig. 3B](#f3-etm-0-0-8992){ref-type="fig"}).

In the control group, the cell cycle of SO-Rb50/VCR cells was 50±2.44% in the G0/G1 phase, 28±2.4% in the G2/M phase, and 32±2.41% in the S phase. After treatment with matrine, the proportion of cells in G0/G1 phase was elevated in a time-dependent manner between 12 and 48 h. After treatment for 12 h, the cells the proportions of cells were 54±3.77% in the G0/G1 phase, 16±0.16% in the G2/M phase and 30±1.76% in the S phase. Following treatment with matrine for 24 h, cells were 68±4.13% in the G0/G1 phase, 7±0.87% in the G2/M phase and 22±1.4% in the S phase. A period of 48 h after treatment, cells were 70±5.08% in the G0/G1 phase, 7±0.65% in the G2/M phase and 19±0.89% in the S phase ([Fig. 4](#f4-etm-0-0-8992){ref-type="fig"}).

### Effect of matrine on Bax, Bcl-2 and cyclin D1 expression

Western blot analysis demonstrated that expression of Bcl-2 protein was significantly downregulated in the matrine-treated group (at IC~50~ concentration) compared with the control group at 12, 24 and 48 h, whereas Bax protein was significantly upregulated at all time-points compared with the control ([Fig. 5A-C](#f5-etm-0-0-8992){ref-type="fig"}).

The expression of Cyclin D1 was significantly downregulated after cells were treated with matrine for 12, 24 and 48 h, compared with the control group ([Fig. 5D](#f5-etm-0-0-8992){ref-type="fig"}).

### Effect of matrine on drug resistance of SO-Rb50/VCR cells

CCK-8 assay was performed to determine the reversal effect of matrine on drug resistance in SO-Rb50/VCR, the IC~50~ value of VCR of SO-Rb50/VCR cells treated with or without matrine for 24 h was 1720±77.4 µg/ml and 1670±103.6 µg/ml, respectively, which indicated that matrine did not affect drug sensitivity after short-term treatment ([Fig. 6](#f6-etm-0-0-8992){ref-type="fig"}).

Discussion
==========

The treatment of retinoblastoma with chemotherapeutic drugs serves an important role in improved clinical outcomes for patients ([@b24-etm-0-0-8992],[@b25-etm-0-0-8992]). However, one of the biggest problems clinicians face is that patients are prone to drug resistance, leading to treatment failure ([@b26-etm-0-0-8992],[@b27-etm-0-0-8992]). In the present study, matrine treatment was indicated to reduce proliferation, induced apoptosis and arrested SO-Rb50/VCR cells cell cycle in the G0/G1 phase. However, matrine did not affect drug sensitivity after short-term treatment. These data suggest matrine may be a potential treatment for VCR-resistant retinoblastoma.

The results of the present study indicated that matrine reduces the proliferation rate of tumor cells SO-Rb50 and SO-Rb50/VCR in a dose-dependent manner. The IC~50~ values of matrine in SO-Rb50 and SO-Rb50/VCR cells after 24 h were 0.96±0.04 mg/ml and 0.97±0.08 mg/ml, respectively. The present study is in agreement with previous studies indicating the anticancer effects of matrine on liver cancer cells, leukemia cells and other tumor cells ([@b28-etm-0-0-8992]). This suggests that matrine treatment may exhibit broad antitumor activity, particularly against VCR-resistant tumor cells.

Apoptosis is not just a simple phenomenon of cell disintegration, but is also closely associated with the onset of a variety of diseases ([@b32-etm-0-0-8992]). Apoptosis is one of the main outcomes induced by different treatments on tumor cells ([@b33-etm-0-0-8992],[@b34-etm-0-0-8992]). The apoptosis induced by matrine occurred in a time-dependent manner. In the present study, the ultrastructures of RB cells were examined using transmission electron microscopy. Before treatment with matrine, SO-Rb50/VCR cells were characterized by a round or ellitical shape with a large nucleus and minimal cytoplasm. Karyokinesis and multinucleated cells were common. After treatment with matrine, apoptosis increased. The findings of the TUNEL assay further demonstrated that matrine treatment could markedly increase the apoptosis rate of SO-Rb50/VCR cells. The Bcl-2-related family of proteins constitutes an important class of either anti-apoptotic (e.g., Bcl-2, Bcl-XL) or pro-apoptotic gene products (including Bax and Bak) ([@b35-etm-0-0-8992]). Bcl-2 directly or indirectly preserves the integrity of the outer mitochondrial membrane, thus promoting cellular survival ([@b36-etm-0-0-8992]). In contrast, the pro-apoptotic Bcl-2 family member Bax, promotes permeabilization and the release of cytochrome C and reactive oxygen species, which are important signals in the apoptosis cascade ([@b37-etm-0-0-8992]). In the present study, the apoptosis-associated protein Bcl-2 was downregulated and the Bax protein was upregulated in SO-Rb50/VCR cells after treatment with matrine.

In addition, the results of the present study showed that the presence of matrine exerted a function in cell cycle compared with control cells. The treated cells accumulated in the G0/G1 phase, and correspondingly, the percentage of cells in the G2/M phase decreased compared with untreated cells. These results suggested that matrine could lead to a shorter DNA synthesis phase in SO-Rb50/VCR cells. This was partially confirmed by the result that matrine reduces the cyclin D1 content in treated cells compared to untreated cells. As a key regulator of cell cycle G1/S transition, cyclin D1 expression has previously been reported to be disturbed in a number of malignancies, due to gene amplification, chromosomal translocation, or mutations ([@b38-etm-0-0-8992]). It has been reported that tumor cells frequently display increased expression of cyclin D1([@b39-etm-0-0-8992]).

The effects of matrine on proliferation, apoptosis and cell cycle arrest of RB cells have been verified by several research groups ([@b40-etm-0-0-8992]). The present study demonstrated a novel function of matrine in treatment of SO-Rb50/VCR cells. Although specific mechanisms were not distinguished, the present study further supports the hypothesis that matrine has broad-spectrum anti-cancer activity. An additional finding of the present study was that matrine did not increase the sensitivity of cells to VCR. This finding differed from previous studies, in which matrine was shown to reverse resistance to paclitaxel ([@b43-etm-0-0-8992]), cisplatin and afatinib ([@b44-etm-0-0-8992]).

In summary, the results of the present study demonstrated that matrine promotes apoptosis of SO-Rb50/VCR cells and arrests the cell cycle. The present study revealed that matrine possesses this function not only in general RB cells but also in vincristine resistant RB cells.
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![Features of SO-Rb50/VCR cells. (A) IC50 value of VCR in SO-Rb50 was significantly increased in SO-Rb50/VCR cells. (B) Western blot analysis was used to determine the expression levels of MDR1/P-gp protein. The level of MDR1/P-gp was increased in SO-Rb50/VCR cells compared with SO-Rb50 cells. ^\*^P\<0.05 vs. SO-Rb50. IC~50~, half-maximal inhibitory concentration; MDR1/P-gp, multi-drug resistance protein 1/p-glycoprotein; SO-RB50/VCR, vincristine-resistant SO-RB50 cells; VCR, vincristine.](etm-20-03-2838-g00){#f1-etm-0-0-8992}

![Matrine inhibits the proliferation of SO-RB50 and SO-RB50/VCR. (A) Proliferation inhibition curves of two RB cell lines treated with different concentrations of matrine for 24 h. Matrine (0.3-1.3 mg/ml; 24 h) exhibited significant suppressive effects on cellular growth of SO-Rb50 and SO-Rb50/VCR cells in a dose-dependent manner. The IC~50~ values of matrine on SO-Rb50 and SO-Rb50/VCR cells for 24 h were 0.96±0.04 mg/ml and 0.97±0.08 mg/ml, respectively. (B) Cell morphology before and after matrine treatment in SO-RB50/VCR cells. SO-Rb50/VCR cells grew as suspended aggregates in a uniform pattern with large nuclei and small cytoplasms. After treatment with matrine (IC~50~) for 24 h, the cell mass was reduced, uneven in size (a) and cytoplasmic debris (b) were observed. IC~50~, half-maximal inhibitory concentration; RB, retinoblastoma; SO-RB50/VCR, vincristine-resistant SO-RB50 cells; VCR, vincristine](etm-20-03-2838-g01){#f2-etm-0-0-8992}

![Matrine triggers apoptosis in SO-RB50/VCR cells. (A) Representative electron microscope images of cell morphology. The cells became uneven in size and cytoplasmic debris (arrow) and vacuolated cells (Triangle) were observed. (B) Apoptosis was detected using flow cytometry in cells treated with matrine for 0 (control), 12, 24 or 48 h. SO-RB50/VCR, vincristine-resistant SO-RB50 cells.](etm-20-03-2838-g02){#f3-etm-0-0-8992}

![Matrine arrests the cell cycle at G0/G1 phase. After treatment with matrine for 0, 12, 24 and 48 h, cell cycle was arrested at G0/G1 phase. Arrows indicate cells at the G1 and G2 phase, respectively.](etm-20-03-2838-g03){#f4-etm-0-0-8992}

![Matrine downregulates Bcl-2 expression and promotes Bax expression in SO-RB50/VCR cells. (A) Representative blots for Bax, Bcl-2 and cyclin D1. (B) Bax expression was promoted after matrine treatment for 0 (control), 12, 24 and 48 h. (C) Bcl-2 expression was reduced after matrine treatment for 0 (control), 12, 24 and 48 h. (D) cyclinD1 expression was reduced after matrine treatment for 0 (control), 12, 24 and 48 h. ^\*\*^P\<0.01 vs. control.](etm-20-03-2838-g04){#f5-etm-0-0-8992}

![Matrine does not affect drug resistance of SO-Rb50/VCR cells to VCR. SO-RB50/VCR, vincristine-resistant SO-RB50 cells; VCR, vincristine.](etm-20-03-2838-g05){#f6-etm-0-0-8992}
